Episode 3: Amy Kruse Talks Venture Investing in Neurotech
What does it take to turn cutting-edge brain science into real-world impact? In this episode of The Business of Neurotech Podcast, host Adam Fraser is joined by Dr Amy Kruse, General Partner and CIO (Chief Investment Officer) at Satori Neuro, whose career spans neuroscience research, DARPA (Defense Advanced Research Projects Agency) program leadership, and venture investing. Dr Kruse shares how her early work in human performance and neurotechnology revealed both the promise and the limitations of emerging tools, and why commercialisation became a key driver of progress. The conversation explores the evolution of the neurotech sector, from early, hardware-heavy systems to today’s ecosystem of scalable platforms, data-driven insights, and investment opportunities. Dr Kruse offers a clear-eyed view on what it takes to build successful neurotech companies, from focusing on core technical breakthroughs to aligning science with commercial milestones. She also discusses the shift toward precision treatment and the long-term potential of technologies that can both treat and prevent neurological challenges. Listen in to hear Dr Amy Kruse’s perspective on where neurotech is heading next!
Key Points From This Episode:
[00:16] Dr Amy Kruse’s journey from neuroscience research and DARPA to Satori Neuro.
[03:52] How these experiences led Dr Kruse to focus on commercialising neurotechnology.
[05:49] Barriers to early neurotech adoption, including hardware limitations.
[08:13] Lessons from DARPA on combining technical progress with commercial milestones.
[10:05] Defining neurotechnology, the brain capital economy, and emerging market terms.
[13:34] The growing role of specialist investors and rising capital in neurotech.
[17:32] Overview of Satori Neuro’s investment approach and focus areas.
[20:03] The role of precision neuroscience and the move toward personalised treatment.
[23:09] Dr Kruse’s current approach to treatment and prevention in neurotech investing.
[25:04] The rise of consumer neurotech and growing interest in personal brain data.
[27:55] Dr Kruse’s preference for platform technologies over single-outcome investments.
[30:01] What she looks for in founders, including self-awareness and coachability.
[34:21] How the potential of Brain-computer interfaces (BCIs) is driving investment and future applications.
[40:02] Where to follow Dr Amy Kruse’s work, including her newsletter and Satori Neuro.
Links Mentioned in Today’s Episode:
